Can a UTI Cause High Bilirubin in Adults?

A urinary tract infection can raise bilirubin levels in adults, though the connection is not as straightforward as it might seem. The liver, not the urinary tract, handles bilirubin processing, so a UTI has to trigger secondary effects before bilirubin climbs. Several distinct pathways make this possible, from the body’s inflammatory response overwhelming normal liver function to bacteria directly destroying red blood cells. Recognizing which mechanism is at work matters because it changes what doctors look for and how aggressively they treat the situation.

How a Urinary Infection Disrupts Liver Function

The most common route from UTI to high bilirubin runs through the liver’s response to infection. When bacteria from a urinary tract infection enter the bloodstream or trigger a strong systemic inflammatory response, the liver’s ability to process and excrete bilirubin can break down. This condition, broadly called sepsis-induced cholestasis, occurs in up to 40% of critically ill patients, with infection being one of the leading triggers.¹ The Surviving Sepsis Campaign defines the liver dysfunction associated with sepsis as bilirubin rising above 2 mg/dL alongside impaired blood clotting.¹

The underlying problem is twofold. First, reduced blood flow and oxygen delivery to the liver during infection impair the liver cells’ ability to take up bilirubin from the blood and move it into bile. Second, bacterial toxins and inflammatory molecules directly interfere with the transport proteins that shuttle bilirubin through liver cells and into the bile ducts. They also damage the structural scaffolding around bile ducts and loosen the tight junctions between liver cells, letting bile components leak back into the bloodstream.¹

Animal research has quantified this disruption. In rats given endotoxin (a component of bacterial cell walls that mimics what happens in bloodstream infections), the liver’s excretion of processed bilirubin dropped by about half. The reduction was not because the liver lost its ability to chemically process bilirubin; rather, the transport machinery for moving bilirubin into bile was impaired at multiple steps, from initial uptake at the blood-facing surface of liver cells to final export into bile.² This distinction matters clinically because it means the liver is structurally intact but functionally stalled, which is why bilirubin typically normalizes once the infection is controlled.

A Real-World Example of How This Gets Missed

The diagnosis is not always obvious. In one published case, a 29-year-old woman arrived at the emergency department with jaundice and symptoms of a urinary tract infection. Clinicians initially suspected Dubin-Johnson syndrome, a rare inherited condition that causes bilirubin buildup, before eventually identifying the cause as sepsis-induced cholestasis from the UTI itself.³ The case highlights a recurring pattern: when a young, otherwise healthy adult develops jaundice alongside what looks like a routine UTI, clinicians may initially look for a liver-specific or genetic explanation and overlook the infection as the direct cause.

This matters because treatment changes depending on the diagnosis. Inherited bilirubin disorders are generally managed conservatively, while sepsis-induced cholestasis requires aggressive treatment of the underlying infection, sometimes including intravenous antibiotics and intensive monitoring. Delayed recognition of the infection’s role can mean delayed treatment of what is actually a serious systemic illness presenting with an unexpected sign.

When UTI-Causing Bacteria Destroy Red Blood Cells

A completely different pathway to high bilirubin involves hemolysis, where bacteria physically break down red blood cells. Bilirubin is a normal byproduct of red blood cell recycling. When red blood cells are destroyed faster than usual, bilirubin production surges beyond what the liver can keep up with, and levels in the blood rise.

Certain bacteria that cause urinary infections produce hemolysins, toxins that punch holes in red blood cell membranes. Alpha-hemolytic and beta-hemolytic strains of common UTI pathogens can trigger this. While much of the published literature on this mechanism comes from neonatal cases, the biology applies across age groups. In one well-documented instance, a hemolytic strain of Enterococcus from a urinary infection caused severe unconjugated hyperbilirubinemia through direct red blood cell destruction.⁴ In adults, E. coli, the bacterium responsible for the majority of urinary infections, also produces hemolysins in many of its uropathogenic strains.

The bilirubin elevation from hemolysis looks different on lab tests than the elevation from cholestasis, which gives clinicians a useful diagnostic clue. Hemolysis produces predominantly unconjugated (indirect) bilirubin because the excess comes from increased production before the liver has processed it. Cholestasis produces predominantly conjugated (direct) bilirubin because the liver has already processed it but cannot excrete it properly. When both processes happen simultaneously during a severe infection, both types rise.

Physical Compression of the Bile Duct

A third and rarer mechanism involves anatomy. When a UTI progresses to acute pyelonephritis, the affected kidney can swell substantially. If it is the right kidney, that swelling can physically compress the common bile duct, which passes nearby. One case report described exactly this scenario: a grossly enlarged right kidney from pyelonephritis distorted the duodenum and compressed the bile duct enough to cause obstructive jaundice. The jaundice resolved with conservative treatment once the kidney infection was brought under control, though the authors noted that a toxic component from the infection itself contributed to the bilirubin rise alongside the mechanical obstruction.⁵

In another unusual report, a giant urinoma (a collection of urine leaking outside the urinary tract after kidney injury) caused both acute pyelonephritis and jaundice through biliary tract compression.⁶ These cases are uncommon, but they illustrate that the connection between urinary infections and high bilirubin is not limited to blood-borne inflammatory pathways. Sometimes the explanation is as simple as one swollen organ pressing on a neighboring structure.

When the Treatment Itself Raises Bilirubin

An underappreciated wrinkle in the UTI-bilirubin question is that some antibiotics used to treat urinary infections can independently cause liver injury. Fluoroquinolones, particularly ciprofloxacin, are widely prescribed for complicated UTIs and pyelonephritis. In rare cases, ciprofloxacin has been linked to significant hepatotoxicity. One case report documented liver biopsy findings of active chronic hepatitis with cholestasis and fibrosis in a patient who developed liver damage following ciprofloxacin exposure.⁷

This creates a diagnostic challenge. If bilirubin rises or fails to improve after a UTI patient starts antibiotics, clinicians have to distinguish between the infection getting worse, antibiotic-induced liver injury, or simply the normal lag between starting treatment and seeing bilirubin normalize. The timing helps: drug-induced liver injury typically emerges days to weeks after starting the medication, whereas sepsis-induced cholestasis is usually present before or at the time antibiotics begin. Still, the overlap can be confusing in clinical practice, and it is worth knowing that the antibiotics themselves are not always innocent bystanders.

Other classes of antibiotics used for UTIs, including trimethoprim-sulfamethoxazole and nitrofurantoin, have also been associated with rare cases of liver injury, though the mechanism and frequency differ. If your bilirubin goes up during or after UTI treatment, your doctor may need to investigate whether the infection, the treatment, or an entirely unrelated liver issue is responsible.

How Bilirubin Levels Track With Infection Severity

Bilirubin is not just a bystander in severe infections; it serves as a clinical marker of how sick someone is. Research on patients with E. coli bloodstream infections, the same bacterium behind most UTIs, has found that a scoring system incorporating bilirubin and albumin levels strongly predicts who will develop septic shock. In a study of 334 patients with E. coli bloodstream infections, about 29% developed septic shock. Patients with the worst bilirubin-albumin scores were roughly seven times more likely to develop shock compared to those with the best scores.⁸

What this means practically is that if you are being treated for a UTI and your bilirubin is climbing, that is not just a lab curiosity. It may signal that the infection is more serious than it initially appeared, potentially progressing toward bloodstream involvement or sepsis. In hospital settings, a rising bilirubin in a patient with a known urinary source of infection often triggers escalation of care, including blood cultures, broader-spectrum antibiotics, and closer monitoring.

The flip side is equally important: a mild UTI that stays confined to the lower urinary tract (a straightforward bladder infection) almost never raises bilirubin to clinically meaningful levels. The bilirubin connection kicks in when the infection becomes systemic or involves the upper urinary tract. If your routine labs during a simple cystitis show mildly elevated bilirubin, the UTI is probably not the explanation, and other causes should be investigated.

What Doctors Look for When UTI and High Bilirubin Overlap

When a patient presents with both a urinary infection and elevated bilirubin, the diagnostic workup has to sort through multiple possibilities beyond the mechanisms described above. The first question is whether the bilirubin elevation is predominantly conjugated or unconjugated, since this narrows the mechanism. Mostly conjugated bilirubin points toward cholestasis or bile duct obstruction. Mostly unconjugated bilirubin points toward hemolysis or, less commonly, impaired liver uptake and processing.

Imaging is often part of the evaluation. Ultrasound of the liver and bile ducts can identify whether the bile ducts are dilated, which would suggest a physical blockage rather than an infection-driven process. In the rare cases where kidney swelling compresses the bile duct, imaging of both the kidneys and the biliary system connects the dots.⁵ Blood tests beyond bilirubin, including liver enzymes, clotting factors, and markers of hemolysis like lactate dehydrogenase and haptoglobin, help distinguish which mechanism is dominant.

Cholestasis from systemic disease can also result from the direct involvement of a disease process within the liver or from immune-mediated changes in bile flow that are secondary to infection elsewhere in the body.⁹ In some cases, conditions that were previously silent, like gallstones or underlying liver disease, are unmasked or worsened by the physiological stress of infection. A thorough evaluation avoids pinning everything on the UTI when a second problem may be contributing.

Recovery and What to Expect

In most cases of infection-driven bilirubin elevation, levels begin dropping once the underlying UTI is effectively treated. The liver’s transport machinery recovers as bacterial toxins and inflammatory signals clear from the bloodstream. For uncomplicated sepsis-induced cholestasis, this recovery typically unfolds over days to a couple of weeks, though it can take longer in patients with pre-existing liver conditions or those who experienced severe sepsis.

If the cause was hemolysis, bilirubin can drop faster because the source of excess production stops as soon as the bacteria are killed. Obstructive causes resolve once the swelling or compression is relieved. Drug-induced liver injury has its own recovery timeline that depends on the severity of the damage and how quickly the offending medication is stopped.

What sometimes alarms patients and clinicians alike is that bilirubin may briefly rise even after appropriate antibiotics are started. This can happen because bacterial die-off releases a surge of endotoxin, temporarily worsening the liver’s transport impairment before things improve. The general trajectory matters more than any single lab value: a steadily climbing bilirubin days into treatment is concerning, while a brief bump followed by a downward trend is usually expected.

Bilirubin’s Surprising Protective Side in Kidney Infections

An interesting footnote to this whole topic is that bilirubin is not purely a waste product or a warning sign. Research has increasingly recognized bilirubin as an antioxidant with genuine protective effects in certain tissues, including the kidneys. In experimental models of pyelonephritis, bilirubin has been studied for its cytoprotective properties. It is the end product of heme oxygenase-1, an enzyme system that has been shown to protect kidney tissue in both acute and chronic kidney injury.¹⁰

This does not mean that high bilirubin during a UTI is beneficial or that anyone should view jaundice as a good sign. But it does reflect a shift in how researchers think about bilirubin. For decades, it was considered purely a metabolic waste product whose elevation signaled disease. The emerging picture is more nuanced: at mildly elevated levels, bilirubin may actually help limit oxidative damage to tissues under stress, including kidneys fighting off infection. At very high levels, of course, it remains toxic, particularly to the brain. The sweet spot, if one exists, is an active area of investigation that may eventually influence how aggressively clinicians target bilirubin levels in infected patients versus focusing exclusively on treating the infection and letting bilirubin sort itself out.